Generic placeholder image

Current Topics in Medicinal Chemistry


ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Review Article

Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity

Author(s): Milica M. Borovcanin*, Gordana D. Radosavljevic, Jelena Pantic, Jelena Milovanovic, Natasa R. Mijailovic, Aleksandar N. Arsenijevic and Nebojsa N. Arsenijevic

Volume 21, Issue 16, 2021

Published on: 02 July, 2021

Page: [1471 - 1487] Pages: 17

DOI: 10.2174/1568026621666210611162420

Price: $65


The role of the Galectin-3 (Gal-3) has already been explored in various somatic diseases, considering its engagement in infection, acute and chronic inflammation, and autoimmunity. Additionally, it has been recognized that Gal-3 is included in neuroinflammation and neurodegeneration, so we presented the possibility for its involvement in neuroprogression in schizophrenia. Gal-3 possibly participates in the early life programming of schizophrenia, also in the specific response to viral infections as a “second hit” later in life, and as a part of a unique systemic somatic dysfunction leading to the specific mental changes. In this review, we would like to put all these previous observations of Gal-3 properties in the context of schizophrenia onset, clinical symptoms presentation, frequent somatic comorbid states, and future options for Gal-3 centered treatment in schizophrenia.

Keywords: Cognition, Comorbidity, Galectin-3, Neuroinflammation, Neurodegeneration, Psychosis, Schizophrenia.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy